2015
PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors
Soares KC, Rucki AA, Wu AA, Olino K, Xiao Q, Chai Y, Wamwea A, Bigelow E, Lutz E, Liu L, Yao S, Anders RA, Laheru D, Wolfgang CL, Edil BH, Schulick RD, Jaffee EM, Zheng L. PD-1/PD-L1 Blockade Together With Vaccine Therapy Facilitates Effector T-Cell Infiltration Into Pancreatic Tumors. Journal Of Immunotherapy 2015, 38: 1-11. PMID: 25415283, PMCID: PMC4258151, DOI: 10.1097/cji.0000000000000062.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaPD-1 blockadeT cellsObjective responsePD-L1PDA patientsPD-1/PD-L1 blockadePD-1/PD-L1 pathwayCytotoxic T-lymphocyte antigen-4Effector T-cell infiltrationPD-1 antibody monotherapyPD-L1 antibody therapySingle-agent checkpoint inhibitorsT-lymphocyte antigen-4Tumor microenvironmentMurine pancreatic ductal adenocarcinomaAddition of vaccineCTLA-4 pathwayImmune suppressive cellsImmune-suppressive signalsPDA tumor microenvironmentPD-L1 blockadeLow-dose cyclophosphamideCD8 T lymphocytesPD-1 antibody
2012
Clinicopathological Characteristics and Molecular Analyses of Multifocal Intraductal Papillary Mucinous Neoplasms of the Pancreas
Matthaei H, Norris AL, Tsiatis AC, Olino K, Hong SM, dal Molin M, Goggins MG, Canto M, Horton KM, Jackson KD, Capelli P, Zamboni G, Bortesi L, Furukawa T, Egawa S, Ishida M, Ottomo S, Unno M, Motoi F, Wolfgang CL, Edil BH, Cameron JL, Eshleman JR, Schulick RD, Maitra A, Hruban RH. Clinicopathological Characteristics and Molecular Analyses of Multifocal Intraductal Papillary Mucinous Neoplasms of the Pancreas. Annals Of Surgery 2012, 255: 326-333. PMID: 22167000, PMCID: PMC3534752, DOI: 10.1097/sla.0b013e3182378a18.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinoma, MucinousAgedAged, 80 and overCarcinoma, Pancreatic DuctalCarcinoma, PapillaryClone CellsFemaleHumansLaser Capture MicrodissectionLoss of HeterozygosityMaleMiddle AgedMutationNeoplasms, Multiple PrimaryNeoplasms, Second PrimaryPancreatic NeoplasmsProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)Ras ProteinsRetrospective StudiesSequence Analysis, DNAConceptsMultifocal intraductal papillary mucinous neoplasmsIntraductal papillary mucinous neoplasmPapillary mucinous neoplasmMucinous neoplasmsClinicopathologic featuresPancreatic cancerClonal relationshipBranch duct lesionsCystic precursor lesionsFamilial pancreatic cancerKRAS gene mutationsIntermediate dysplasiaIndependent genetic alterationsDuct lesionsClinicopathological characteristicsInvasive cancerPrecursor lesionsPartial pancreatectomyPatientsNeoplasmsIntermediate gradeGene mutationsCancerGenetic alterationsMolecular analysis
2011
Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent
Mayo SC, Nathan H, Cameron JL, Olino K, Edil BH, Herman JM, Hirose K, Schulick RD, Choti MA, Wolfgang CL, Pawlik TM. Conditional survival in patients with pancreatic ductal adenocarcinoma resected with curative intent. Cancer 2011, 118: 2674-2681. PMID: 21935914, PMCID: PMC3578343, DOI: 10.1002/cncr.26553.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAgedAged, 80 and overCarcinoma, Pancreatic DuctalFemaleHumansMaleMiddle AgedPancreatic NeoplasmsPrognosisProportional Hazards ModelsSEER ProgramConceptsPancreatic ductal adenocarcinomaConditional survivalConditional survival estimatesActuarial survivalCurative intentPositive marginsSurvival estimatesDuctal adenocarcinomaResection of PDACPostoperative year 5Date of surgeryCox regression analysisPredictors of survivalTime of surgeryMedian survivalMargin statusWorse survivalHigher lymphKaplan-MeierTumor sizeLarge cohortPatientsMultivariate analysisLymphSurgeryLoss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas
Hong SM, Li A, Olino K, Wolfgang CL, Herman JM, Schulick RD, Iacobuzio-Donahue C, Hruban RH, Goggins M. Loss of E-cadherin expression and outcome among patients with resectable pancreatic adenocarcinomas. Modern Pathology 2011, 24: 1237-1247. PMID: 21552209, PMCID: PMC3155013, DOI: 10.1038/modpathol.2011.74.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaE-cadherin expressionPancreatic adenocarcinomaDuctal adenocarcinomaIndependent predictorsPoor outcomeCox proportional hazards regression modelingProportional hazards regression modelingPancreatic cancer outcomesWorse median survivalResectable pancreatic adenocarcinomaMinority of patientsKaplan-Meier analysisE-cadherin statusMedian survivalSurgical resectionWorse prognosisCancer outcomesSubgroup analysisPathological factorsPatient outcomesCell adhesion moleculeMortality riskTissue microarrayPartial lossPresence of Pancreatic Intraepithelial Neoplasia in the Pancreatic Transection Margin does not Influence Outcome in Patients with R0 Resected Pancreatic Cancer
Matthaei H, Hong SM, Mayo SC, dal Molin M, Olino K, Venkat R, Goggins M, Herman JM, Edil BH, Wolfgang CL, Cameron JL, Schulick RD, Maitra A, Hruban RH. Presence of Pancreatic Intraepithelial Neoplasia in the Pancreatic Transection Margin does not Influence Outcome in Patients with R0 Resected Pancreatic Cancer. Annals Of Surgical Oncology 2011, 18: 3493-3499. PMID: 21537863, PMCID: PMC3166423, DOI: 10.1245/s10434-011-1745-9.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaPancreatic intraepithelial neoplasiaResection marginsTransection marginR0 resectionIntraepithelial neoplasiaPanIN lesionsPanIN-3High-grade PanIN lesionsImportant clinicopathologic characteristicsPancreatic resection marginPancreatic transection marginPresence of PanINOverall median survivalIntraoperative frozen sectionSignificant survival differenceSignificant clinical implicationsGrades of PanINsR1 resectionStrong prognosticatorMedian survivalAdditional resectionClinicopathologic characteristicsClinicopathologic factorsSurgical margins
2010
Immuno- and gene-therapeutic strategies targeted against cancer (mainly focusing on pancreatic cancer)
Yoshimura K, Olino K, Edil BH, Schulick RD, Oka M. Immuno- and gene-therapeutic strategies targeted against cancer (mainly focusing on pancreatic cancer). Surgery Today 2010, 40: 404-410. PMID: 20425541, DOI: 10.1007/s00595-009-4120-8.Peer-Reviewed Original ResearchMeSH KeywordsAnimalsCancer VaccinesCarcinoma, Pancreatic DuctalClinical Trials as TopicDisease Models, AnimalGenetic TherapyHumansImmunotherapyNeoplasm Recurrence, LocalNeoplasmsPancreatic NeoplasmsConceptsCurrent treatment modalitiesNovel therapeutic approachesGene therapySurgical resectionTreatment arsenalTumor recurrenceCancer patientsTreatment modalitiesClinical trialsTherapeutic approachesGene therapeutic strategiesVivo modelCancerImmunotherapyTherapyFurther investigationPotential additionResectionChemotherapyPatientsRecurrenceMortalityTrialsCare